All this and more!!
Hemophilia A Gene, Cell Therapy Combo Shows Promise, Study Reports (hemophilianewstoday.com) …..and this
Sernova’s Collaborator to Present Cell Pouch™ Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeting
February 3, 2021 - 9:00 a.m. EST
LONDON, ONTARIO – February 3, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that Dr. Sam Wiseman, BSc, MD, FRCSC, FACS of the University of British Columbia and co-investigator of Sernova’s Cell Pouch Hypothyroid treatment program will present preclinical data in an oral presentation at the American Association of Endocrine Surgeons (AAES) 2021 Annual Meeting taking place April 25-27, 2021. Dr. Sam Wiseman, Professor, Richard J. Finley Scholar, and Director of Research at the Department of Surgery of Providence Health Care also serves as Chair of the Endocrine Tumor Group for the Surgical Oncology Network in Vancouver British Columbia.
Dr. Wiseman’s abstract was selected amongst over 140 abstracts for an Oral Podium Presentation and a resulting journal article will be peer-reviewed for publication consideration in the journal Surgery.
For more information on the American Association of Endocrine Surgeons and the 41st Annual Meeting, visit https://meeting.endocrinesurgery.org/.
ABOUT SERNOVA’S HYPOTHYROID PROGRAM
Sernova’s initial approach in treating hypothyroid disease is to transplant a patient’s own healthy thyroid tissue following thyroidectomy into the pre-implanted vascularized Cell Pouch to recover the normal function of the thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work is being conducted under a grant from the British Columbia Transplant Foundation. Following successful completion of preclinical studies, Sernova plans to conduct clinical assessments of the Cell Pouch with transplanted thyroid tissue in patients suffering from hypothyroid disease with the aim to preserve thyroid function and improve patient quality of life.
Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non- cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation are diagnosed with benign diseases after their procedure. Patients with Grave’s disease and thyroid nodules undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. The development of new therapeutic strategies to overcome hypothyroidism remains an important unmet medical need.
News alert…. Nice SVA BTV commercial
https://b-tv.com/sernova-a-functional-cure-for-type-i-diabetes-news-alert-60sec/ ALSO…
bought a deal for $20M….. oversubscribed by 100%.... and huge demand that most were not able to get in on….
there is lots to love and hate about this placement…I love not so much the full warrants with the deal… but this.... plus recently cashed warrants gives them more cash, $25M, than they had at one time… ever….…. Sernova has their reasons for using Cannacord.... and shared this:
Sigilon Therapeutics
December 2020
Canaccord Genuity Acted as a Bookrunner in an Initial Public Offering for Sigilon Therapeutics, Inc.
Transaction Overview: Sigilon Therapeutics, Inc. (the “Company”) (Nasdaq:SGTX), priced its $126 million upsized initial public offering on December 3, 2020 at a price of $18 per share. The Company issued 7,000,000 shares of common stock. The Underwriters exercised their option to purchase an additional $1,050,000 shares of common stock at the initial public offering price, bringing the total proceeds to $144.9 million, less the underwriting discounts and commissions.
Company Overview:
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis.
ALSO……
Sernova Corp.'s shares have started trading on Xetra, the electronic trading system of Deutsche Borse AG in Germany …. approximately 90 percent of all trading in shares across all German exchanges is now conducted through Xetra making it the largest of Germany's stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and Hong Kong are connected via Xetra servers.
Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities are executed swiftly and at prices in line with the market. Moreover, this principle is supported by Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure additional liquidity and fair prices, making it the first choice for institutional investors. mwb Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of Sernova's shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.
……APPARENTLY, the European equivalent of NASDAQ.
LOOKS PRETTY POSITIVE TO ME...HOW ABOU YOU?
oh... and I think this is a new tag at the bottom of news..... and I like it.
ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com